Head and neck cancer is an understudied disease with a high relapse and mortality rate. Therapeutic modalities have not significantly improved since the last 40 years. Even though immunotherapy is providing promising results, currently it is only applicable to metastatic patients. Finding new therapies for HNSCC patients is the main objective and challenge for basic and clinical researchers. With the idea of promoting new challenges and future applications for medium term applicability to HNSCC patients.